Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06578585 · ClinicalTrials.gov registry record · Phase 1
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT06578585 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 43 participants.
The verdict
NCT06578585, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.
Interventions
- DRUG Placebo
- DRUG Ubrogepant
- DRUG Lu AG09222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-09-13 |
| Est. Completion | 2025-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06578585
The ClinicalTrials.gov registry entry for NCT06578585 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06578585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06578585 about?
NCT06578585 is a clinical study titled "A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine". The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepa...
What is the current status of trial NCT06578585?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2024-09-13. Estimated completion is 2025-07-11.
What interventions are being tested in trial NCT06578585?
The interventions under investigation include: Placebo (DRUG), Ubrogepant (DRUG), Lu AG09222 (DRUG).
Who is sponsoring clinical trial NCT06578585?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.